Purification process development for HER1 extracellular domain as a potential therapeutic vaccine
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-10-01
著者
-
Montero Jose
Monoclonal Antibody Production Department Center For Genetic Engineering And Biotechnology
-
Valdes Rodolfo
Monoclonal Antibody Division Center For Genetic Engineering And Biotechnology
-
Pena Vladimir
Process Development Department Center For Molecular Immunology
-
Prieto Yadira
Process Development Department Center For Molecular Immunology
-
Castillo Adolfo
Process Development Department Center For Molecular Immunology
-
De La
Process Development Department Center For Molecular Immunology
-
Palacios Julio
Process Development Department Center For Molecular Immunology
-
LEON Dania
Process Development Department, Center for Molecular Immunology
-
FERNANDEZ Eutimio
Inorganic Chemistry Department, Center for Engineering and Chemical Researches, F Street
-
PEREZ Noemi
Process Development Department, Center for Molecular Immunology
-
BULTE Dubhe
Technologies Development Department, Center for Molecular Immunology
-
FERRO Williams
Monoclonal Antibody Production Department, Center for Genetic Engineering and Biotechnology
-
SANCHEZ Belinda
Vaccine Department, Center for Molecular Immunology
-
Ferro Williams
Monoclonal Antibody Production Department Center For Genetic Engineering And Biotechnology
-
Sanchez Belinda
Vaccine Department Center For Molecular Immunology
-
Fernandez Eutimio
Inorganic Chemistry Department Center For Engineering And Chemical Researches F Street
-
Leon Dania
Process Development Department Center For Molecular Immunology
-
Bulte Dubhe
Technologies Development Department Center For Molecular Immunology
-
Perez Noemi
Process Development Department Center For Molecular Immunology
関連論文
- Comparison of different ligand densities in immunoaffinity chromatography of the plantibody HB-01 coupled to Sepharose CL-4B to purify the rHBsAg
- Stirrer tank : an appropriate technology to immobilize the CB. Hep-1 monoclonal antibody for immunoaffinity purification
- Purification process development for HER1 extracellular domain as a potential therapeutic vaccine